Tekmira Names Ebola Virus Rx as Third Clinical Candidate

The company also continues to make advances with its investigational cancer therapy and its bid to list its shares in the US, and said it expects "to be listed in Nasdaq in the next one to two months."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.